Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery of next-generation drug conjugates globally. The financial details of the partnership have not been disclosed.
Integration of Core Technologies
Nona Bio will utilize the biological enzyme solid-phase catalytic coupling technology platforms, iLDC and iGDC, which are independently developed by GeneQuantum. These platforms will be combined with Nona Bio’s leading technology and extensive resources in the antibody field, exemplified by the Harbor Mice platform. This synergy will further expand Nona Bio’s technology platform capabilities and enhance its ability to provide global partners with a comprehensive solution for the early detection of conjugated drugs.
Expanding Global Reach and Capabilities
Through this strategic partnership, Nona Biosciences is poised to strengthen its position at the forefront of drug conjugate discovery. The integration of GeneQuantum’s proprietary technologies with Nona Bio’s expertise in antibody development will create a robust platform for innovation, enabling the companies to offer a one-stop solution for the early detection and development of next-generation drug conjugates. This collaboration is expected to accelerate the discovery process and bring new, effective treatments to market more efficiently.- Flcube.com
